Comparison · NCT02746991-sae
FAI Insert vs Sham Injection: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. FAI Insert vs Sham Injection: serious adverse events. Trial comparisons, record NCT02746991-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02746991-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.208 | 0.14 | 0.297 | wilson | |
| Risk in group 2 | 0.135 | 0.0668 | 0.253 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0733 | -0.0628 | 0.185 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.54 | 0.703 | 3.39 | log | |
| Odds ratio, group 1 over group 2 | 1.69 | 0.666 | 4.28 | log | |
| Number needed to harm, for one more participant with a serious adverse event on FAI Insert than on Sham Injection | 13.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | FAI Insert | FAI Insert Group | 21 | 101 | EG001 |
| Group 2 | Sham Injection | Placebo Injection | 7 | 52 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
36 months. All Adverse Event (AE)s will be evaluated from their onset until resolution, stabilization, last day of participation in the study of the patient or the last day of the study, whichever is first.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
- NCT number
- NCT02746991
- Phases
- PHASE3
- Conditions
- Posterior Uveitis, Intermediate Uveitis, Panuveitis
- Interventions
- Sham Injection, FAI Insert
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Results first posted
- 2020-07-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02746991?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02746991-sae